GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Classifica tra le azioni
#3636
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Prezzo delle azioni
$27.54
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$4.67B
Variazione (1 giorno)
-2.73%
Variazione (1 anno)
-11.86%
Paese
IN
Scambia GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Categoria
Healthcare
Rapporto P/S per GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Rapporto P/S al October 2026 TTM: 10.72
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di GlaxoSmithKline Pharmaceuticals Limited, il rapporto P/S attuale (TTM) è 10.72. Alla fine del 2024, era pari a 9.74.
Storico del rapporto P/S per GlaxoSmithKline Pharmaceuticals Limited da 2004 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 10.72 | -15.16% |
| 2025 | 12.64 | 29.73% |
| 2024 | 9.74 | 41.17% |
| 2023 | 6.90 | -19.88% |
| 2022 | 8.61 | 3.26% |
| 2021 | 8.34 | 26.28% |
| 2020 | 6.61 | -6.14% |
| 2019 | 7.04 | 13.41% |
| 2018 | 6.21 | -22.36% |
| 2017 | 7.99 | -31.64% |
| 2016 | 11.69 | 6.32% |
| 2015 | 11.00 | 10.60% |
| 2013 | 9.94 | 43.71% |
| 2012 | 6.92 | -0.12% |
| 2011 | 6.93 | -24.74% |
| 2010 | 9.20 | 28.61% |
| 2009 | 7.16 | 24.35% |
| 2008 | 5.76 | 6.38% |
| 2007 | 5.41 | -12.92% |
| 2006 | 6.21 | -1.99% |
| 2005 | 6.34 | 32.89% |
| 2004 | 4.77 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 14.32 | 33.54% |
US
|
|
| 6.16 | -42.56% |
US
|
|
| 7.78 | -27.45% |
US
|
|
| 5.48 | -48.88% |
US
|
|
| 4.66 | -56.56% |
CH
|
